Here are five things to know:
• Integra Lifesciences has received a consensus rating of “Buy” from the seven analysts that are covering the company.
• The company has a one-year low of $42.50 and a one-year high of $61.26.
• The stock’s 50-day moving average is $57.
• The stock’s 200-day moving average is $51.
• The company has a market cap of $1.97 billion.
More articles on devices:
NuVasive, Medtronic patent saga continues — 5 key updates
InVivo goes from illiquid to a top-traded stock: 5 key notes
6 key notes on Mazor Robotics’ short interest decline
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
